Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPERT: Photodynamic Therapy for Metastatic Brain Tumors
jRCTs031260087Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2026
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of talaporfin sodium in brain neoplasm (2 cohorts), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: 6-month local recurrence rate at the surgical site. Started May 2026; status: recruiting.
02
Drugs
talaporfin sodium
03
Conditions
brain neoplasm
Beyond the preview
Go deeper on jRCTs031260087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260087.